Influence of Metabolic Risk Factors on Risk of Hepatocellular Carcinoma and Liver-Related Death in Men With Chronic Hepatitis B: A Large Cohort Study

Gastroenterology

Volumn 153, Issue 4, 2017, Pages 1006-1017.e5

  Yu, Ming Whei ^a   Lin, Chih Lin ^b   Liu, Chun Jen ^c   Yang, Shu Han ^a   Tseng, Yu Lin ^a   Wu, Chih Feng ^a  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b TAIPEI CITY HOSPITAL   (Taiwan)

^c NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

ALT; Fatty Liver; GGT; Liver Cancer

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CHOLESTEROL; GLUCOSE; TRIACYLGLYCEROL;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BODY MASS; CANCER INCIDENCE; CANCER MORTALITY; CANCER RISK; CHOLESTEROL BLOOD LEVEL; CHRONIC HEPATITIS B; CHRONIC LIVER DISEASE; COHORT ANALYSIS; CONTROLLED STUDY; DIABETES MELLITUS; FOLLOW UP; GLUCOSE BLOOD LEVEL; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; INSULIN RESISTANCE; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; OBESITY; PRIORITY JOURNAL; RISK FACTOR; SMOKING; TAIWANESE; TRIACYLGLYCEROL BLOOD LEVEL; ADVERSE EFFECTS; AGED; CARCINOMA, HEPATOCELLULAR; COMPARATIVE STUDY; FACTUAL DATABASE; HEPATITIS B, CHRONIC; INCIDENCE; LIVER NEOPLASMS; METABOLIC SYNDROME X; MIDDLE AGED; PROGNOSIS; RISK ASSESSMENT; TAIWAN; TIME FACTOR;

ADULT; AGED; CARCINOMA, HEPATOCELLULAR; DATABASES, FACTUAL; DIABETES MELLITUS; HEPATITIS B, CHRONIC; HUMANS; HYPERTENSION; HYPERTRIGLYCERIDEMIA; INCIDENCE; LIVER NEOPLASMS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; OBESITY; PROGNOSIS; RISK ASSESSMENT; RISK FACTORS; SMOKING; TAIWAN; TIME FACTORS;

EID: 85031670161     PISSN: 00165085     EISSN: 15280012     Source Type: Journal    
DOI: 10.1053/j.gastro.2017.07.001     Document Type: Article

References (40)

1. El-Serag, H.B., Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology 142 (2012), 1264–1273.
2. Yu, M.W., Yeh, S.H., Chen, P.J., et al. Hepatitis B virus genotype and DNA level and hepatocellular carcinoma: a prospective study in men. J Natl Cancer Inst 97 (2005), 265–272.
3. Chen, C.J., Yang, H.I., Su, J., et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 295 (2006), 65–73.
4. Tseng, T.C., Liu, C.J., Yang, H.C., et al. High levels of hepatitis B surface antigen increase risk of hepatocellular carcinoma in patients with low HBV load. Gastroenterology 142 (2012), 1140–1149.
5. Wu, C.F., Yu, M.W., Lin, C.L., et al. Long-term tracking of hepatitis B viral load and the relationship with risk for hepatocellular carcinoma in men. Carcinogenesis 29 (2008), 106–112.
6. Hung, Y.C., Lin, C.L., Liu, C.J., et al. Development of risk scoring system for stratifying population for hepatocellular carcinoma screening. Hepatology 61 (2015), 1934–1944.
7. Yu, M.W., Shih, W.L., Lin, C.L., et al. Body-mass index and progression of hepatitis B: a population-based cohort study in men. J Clin Oncol 26 (2008), 5576–5582.
8. Chao, L.T., Wu, C.F., Sung, F.Y., et al. Insulin, glucose and hepatocellular carcinoma risk in male hepatitis B carriers: results from 17-year follow-up of a population-based cohort. Carcinogenesis 32 (2011), 876–881.
9. Rinella, M.E., Nonalcoholic fatty liver disease: a systematic review. JAMA 313 (2015), 2263–2273.
10. Dyson, J., Jaques, B., Chattopadyhay, D., et al. Hepatocellular cancer: the impact of obesity, type 2 diabetes and a multidisciplinary team. J Hepatol 60 (2014), 110–117.
11. Farrell, G.C., Wong, V.W., Chitturi, S., NAFLD in Asia-as common and important as in the West. Nat Rev Gastroenterol Hepatol 10 (2013), 307–318.
12. Wong, G.L., Wong, V.W., Choi, P.C., et al. Metabolic syndrome increases the risk of liver cirrhosis in chronic hepatitis B. Gut 58 (2009), 111–117.
13. Ekstedt, M., Franzén, L.E., Mathiesen, U.L., et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology 44 (2006), 865–873.
14. Welzel, T.M., Graubard, B.I., Zeuzem, S., et al. Metabolic syndrome increases the risk of primary liver cancer in the United States: a study in the SEER-Medicare database. Hepatology 54 (2011), 463–471.
15. Bhala, N., Angulo, P., van der Poorten, D., et al. The natural history of nonalcoholic fatty liver disease with advanced fibrosis or cirrhosis: an international collaborative study. Hepatology 54 (2011), 1208–1216.
16. Angulo, P., Bugianesi, E., Bjornsson, E.S., et al. Simple noninvasive systems predict long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology 145 (2013), 782–789.
17. Ekstedt, M., Hagström, H., Nasr, P., et al. Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. Hepatology 61 (2015), 1547–1554.
18. Mittal, S., El-Serag, H.B., Sada, Y.H., et al. Hepatocellular carcinoma in the absence of cirrhosis in United States veterans is associated with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 14 (2016), 124–131.
19. Adams, L.A., Lymp, J.F., St Sauver, J., et al. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology 129 (2005), 113–121.
20. Baffy, G., Brunt, E.M., Caldwell, S.H., Hepatocellular carcinoma in non-alcoholic fatty liver disease: an emerging menace. J Hepatol 56 (2012), 1384–1391.
21. Saunders, D., Seidel, D., Allison, M., et al. Systematic review: the association between obesity and hepatocellular carcinoma - epidemiological evidence. Aliment Pharmacol Ther 31 (2010), 1051–1063.
22. Calle, E.E., Rodriguez, C., Walker-Thurmond, K., et al. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 348 (2003), 1625–1638.
23. Adami, H.O., Chow, W.H., Nyrén, O., et al. Excess risk of primary liver cancer in patients with diabetes mellitus. J Natl Cancer Inst 88 (1996), 1472–1477.
24. Chen, C.L., Yang, H.I., Yang, W.S., et al. Metabolic factors and risk of hepatocellular carcinoma by chronic hepatitis B/C infection: a follow-up study in Taiwan. Gastroenterology 135 (2008), 111–121.
25. Schlesinger, S., Aleksandrova, K., Pischon, T., et al. Diabetes mellitus, insulin treatment, diabetes duration, and risk of biliary tract cancer and hepatocellular carcinoma in a European cohort. Ann Oncol 24 (2013), 2449–2455.
26. Maison, P., Byrne, C.D., Hales, C.N., et al. Do different dimensions of the metabolic syndrome change together over time? Evidence supporting obesity as the central feature. Diabetes Care 24 (2001), 1758–1763.
27. World Health Organization. Obesity: preventing and managing the global epidemic: Report of a WHO consultation. WHO Technical Report Series, 894. 2000, WHO, Geneva.
28. Matthews, D.R., Hosker, J.P., Rudenski, A.S., et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28 (1985), 412–419.
29. Barlow, W.E., Robust variance estimation for the case-cohort design. Biometrics 50 (1994), 1064–1072.
30. Azzalini, L., Ferrer, E., Ramalho, L.N., et al. Cigarette smoking exacerbates nonalcoholic fatty liver disease in obese rats. Hepatology 51 (2010), 1567–1576.
31. DeBoer, M.D., Gurka, M.J., Morrison, J.A., et al. Inter-relationships between the severity of metabolic syndrome, insulin and adiponectin and their relationship to future type 2 diabetes and cardiovascular disease. Int J Obes (Lond) 40 (2016), 1353–1359.
32. Jarcuska, P., Drazilova, S., Fedacko, J., et al. Association between hepatitis B and metabolic syndrome: Current state of the art. World J Gastroenterol 22 (2016), 155–164.
33. Jinjuvadia, R., Liangpunsakul, S., Association between metabolic syndrome and its individual components with viral hepatitis B. Am J Med Sci 347 (2014), 23–27.
34. Schoeman, J.C., Hou, J., Harms, A.C., et al. Metabolic characterization of the natural progression of chronic hepatitis B. Genome Med, 8, 2016, 64.
35. Shi, Y.X., Huang, C.J., Yang, Z.G., Impact of hepatitis B virus infection on hepatic metabolic signaling pathway. World J Gastroenterol 22 (2016), 8161–8167.
36. Lloyd-Jones, D.M., Cardiovascular risk prediction: basic concepts, current status, and future directions. Circulation 121 (2010), 1768–1777.
37. Detterbeck, F.C., Mazzone, P.J., Naidich, D.P., et al. Screening for lung cancer: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 143:5 Suppl (2013), e78S–e92S.
38. Ascha, M.S., Hanouneh, I.A., Lopez, R., et al. The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. Hepatology 51 (2010), 1972–1978.
39. Lee, D.H., Blomhoff, R., Jacobs, D.R. Jr., Is serum gamma glutamyltransferase a marker of oxidative stress?. Free Radic Res 38 (2004), 535–539.
40. Chiolero, A., Faeh, D., Paccaud, F., et al. Consequences of smoking for body weight, body fat distribution, and insulin resistance. Am J Clin Nutr 87 (2008), 801–809.